Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/µl? Impact on immunovirological parameters
- 24 August 2005
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 77 (2), 164-172
- https://doi.org/10.1002/jmv.20452
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease InhibitorsJournal of Virology, 2004
- Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cellsAIDS, 2004
- HIV Type 1 DNA Development during Long-Term Supervised Therapy InterruptionAIDS Research and Human Retroviruses, 2003
- Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment responseAIDS, 2003
- Predictive Value of Provirus Load and DNA Human Immunodeficiency Virus Genotype for Successful Abacavir‐Based Simplified TherapyThe Journal of Infectious Diseases, 2003
- Evolution of Human Immunodeficiency Virus Type 1 Populations after Resumption of Therapy following Treatment Interruption and Shift in Resistance GenotypeThe Journal of Infectious Diseases, 2002
- HIV-1 DNA Burden in Peripheral Blood CD4+Cells Influences Disease Progression, Antiretroviral Efficacy, and CD4+T-Cell RestorationViral Immunology, 2001
- Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral TherapyJournal of Virology, 2001
- HIV RNA and HIV DNA in Peripheral Blood Mononuclear Cells Are Consistent Markers for Estimating Viral Load in Patients Undergoing Long-Term Potent TreatmentAIDS Research and Human Retroviruses, 2000
- Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNAAIDS, 2000